136,800 Shares in Savara Inc. $SVRA Acquired by Swiss National Bank

Swiss National Bank purchased a new stake in Savara Inc. (NASDAQ:SVRA) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 136,800 shares of the company’s stock, valued at approximately $747,000. Swiss National Bank owned 0.07% of Savara at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Rhumbline Advisers boosted its position in Savara by 10.8% during the second quarter. Rhumbline Advisers now owns 170,176 shares of the company’s stock worth $388,000 after purchasing an additional 16,634 shares during the period. Prudential Financial Inc. acquired a new position in shares of Savara in the second quarter valued at $30,000. XTX Topco Ltd bought a new position in shares of Savara in the second quarter valued at about $201,000. Invesco Ltd. raised its position in shares of Savara by 35.4% in the second quarter. Invesco Ltd. now owns 120,891 shares of the company’s stock valued at $276,000 after purchasing an additional 31,633 shares during the period. Finally, The Manufacturers Life Insurance Company raised its position in shares of Savara by 14.2% in the second quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock valued at $118,000 after purchasing an additional 6,449 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Stock Performance

Shares of NASDAQ SVRA opened at $5.46 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.47 and a quick ratio of 13.47. The firm has a market cap of $1.12 billion, a price-to-earnings ratio of -9.75 and a beta of 0.24. The stock’s fifty day moving average price is $5.58 and its two-hundred day moving average price is $5.51. Savara Inc. has a one year low of $2.43 and a one year high of $7.01.

Savara (NASDAQ:SVRA) last posted its earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). On average, equities analysts forecast that Savara Inc. will post -0.57 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently commented on SVRA. Oppenheimer started coverage on shares of Savara in a report on Friday, April 24th. They set an “outperform” rating and a $11.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Friday, July 17th. Finally, Wall Street Zen raised shares of Savara from a “sell” rating to a “hold” rating in a report on Saturday, June 13th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $10.14.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.